Author/Editor		Fettich, J; Nair, G; Padhy, AK; Stare, J; Nair, N; Moralles, R; Tanumihardia, M; Riccabona, G
Title		32-phosphorus for bone pain palliation due to bone metastases, its safety and efficacy in patients with advanced cancer
Type		članek
Source		IAEA-TECDOC
Vol. and No.		, št. 1228
Publication year		2001
Volume		str. 193-8
Language		eng
Abstract		Bone pain due to bony metastases can seriously affect a patient's quality of life. External irradiation, narcotic drugs and polyphosphates may cause important side effects or are expensive, therefore in many patients radionuclide treatment using a single dose of beta emitting bone seeking radiopharmaceuticals has become widely accepted. Except 32-Phosphorus (32-P) all of them are expensive and difficult to obtain in certain countries. The aim of the study was to evaluate safety and efficacy of 32-P for palliation of bone pain due to bony metastases by comparing it to 89-Strontium (89-Sr), the most commonly used radiopharmaceutical for bone pain palliation in the framework of a prospective IAEA co-ordinated multicenter study. A very strict protocol for unified patient inclusion and follow up was used. 93 cancer patients with osteoblastic bony metastases were included into the study, 48 were treated by 89-Sr (150 MBq) and 45 by 32-P (450 MBq). Pain score, analgesic consumption, quality of life, and indices of bone marrow depression were monitored 2 weeks pre- and up to 4 months post treatment. Favourable response to treatment was recorded in 75% of the patients treated with 89-Sr and in 60% of those treated with 32-P (p=0,122). There was no significant difference between the duration of favourable effect for both radiopharmaceuticals. Moderate decrease of white blood cell (WBC) and platelet counts, and haemoglobin (Hb) levels was detected more often in the 32-P treated group. Although 32-P appears to be more toxic, no toxic effects requiring specific treatment were seen in either group. Due to its comparable efficacy and safety, general availability and low cost its more widespread use should be encouraged to increase quality of life and reduce cost of medical care of patients with intractable bone pain due to cancer metastases.
Descriptors		NEOPLASM METASTASIS BONE NEOPLASMS PAIN MEASUREMENT PHOSPHORUS RADIOISOTOPES STRONTIUM RADIOISOTOPES ANALGESICS BONE MARROW QUALITY OF LIFE TREATMENT OUTCOME